PAIN
Volume 149, Issue 2 , Pages 177-193 , May 2010

Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations

  • Robert H. Dworkin

      Affiliations

    • Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, NY, 14642, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 585 275 3524; fax: +1 585 473 5007.
    • ,
  • Dennis C. Turk

      Affiliations

    • University of Washington, Seattle, WA, USA
    • ,
  • Sarah Peirce-Sandner

      Affiliations

    • Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, NY, 14642, USA
    • ,
  • Ralf Baron

      Affiliations

    • University of Kiel, Kiel, Germany
    • ,
  • Nicholas Bellamy

      Affiliations

    • University of Queensland, Brisbane, Australia
    • ,
  • Laurie B. Burke

      Affiliations

    • United States Food and Drug Administration, Silver Spring, MD, USA
    • ,
  • Amy Chappell

      Affiliations

    • Eli Lilly & Co., Indianapolis, IN, USA
    • ,
  • Kevin Chartier

      Affiliations

    • United BioSource Corporation, Newtown, PA, USA
    • ,
  • Charles S. Cleeland

      Affiliations

    • M.D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Ann Costello

      Affiliations

    • United States Food and Drug Administration, Silver Spring, MD, USA
    • ,
  • Penney Cowan

      Affiliations

    • American Chronic Pain Association, Rocklin, CA, USA
    • ,
  • Rozalina Dimitrova

      Affiliations

    • Allergan, Inc, Irvine, CA, USA
    • ,
  • Susan Ellenberg

      Affiliations

    • New York University, New York, NY, USA
    • ,
  • John T. Farrar

      Affiliations

    • New York University, New York, NY, USA
    • ,
  • Jacqueline A. French

      Affiliations

    • New York University, New York, NY, USA
    • ,
  • Ian Gilron

      Affiliations

    • Queen’s University, Kingston, Ontario, Canada
    • ,
  • Sharon Hertz

      Affiliations

    • United States Food and Drug Administration, Silver Spring, MD, USA
    • ,
  • Alejandro R. Jadad

      Affiliations

    • University of Toronto, Toronto, Canada
    • ,
  • Gary W. Jay

      Affiliations

    • Schwarz Biosciences, Research Triangle Park, NC, USA
    • ,
  • Jarkko Kalliomäki

      Affiliations

    • AstraZeneca, Södertälje, Sweden
    • ,
  • Nathaniel P. Katz

      Affiliations

    • Analgesic Research, Needham, MA, USA
    • ,
  • Robert D. Kerns

      Affiliations

    • Department of Veterans Affairs, West Haven, CT, USA
    • ,
  • Donald C. Manning

      Affiliations

    • Celgene Corporation, Warren, NJ, USA
    • ,
  • Michael P. McDermott

      Affiliations

    • University of Rochester, Rochester, NY, USA
    • ,
  • Patrick J. McGrath

      Affiliations

    • IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada
    • ,
  • Arvind Narayana

      Affiliations

    • Cephalon, Inc., Frazer, PA, USA
    • ,
  • Linda Porter

      Affiliations

    • National Institutes of Health, Bethesda, MD, USA
    • ,
  • Steve Quessy

      Affiliations

    • qd consulting, LLC, Research Triangle Park, NC, USA
    • ,
  • Bob A. Rappaport

      Affiliations

    • United States Food and Drug Administration, Silver Spring, MD, USA
    • ,
  • Christine Rauschkolb

      Affiliations

    • Johnson & Johnson Pharmaceutical Research & Development LLC, Raritan, NJ, USA
    • ,
  • Bryce B. Reeve

      Affiliations

    • National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    • ,
  • Thomas Rhodes

      Affiliations

    • Merck & Company, Blue Bell, PA, USA
    • ,
  • Cristina Sampaio

      Affiliations

    • Faculdade de Medicina de Lisboa, Lisbon, Portugal
    • ,
  • David M. Simpson

      Affiliations

    • Mt. Sinai School of Medicine, New York, NY, USA
    • ,
  • Joseph W. Stauffer

      Affiliations

    • Alpharma, Piscataway, NJ, USA
    • ,
  • Gerold Stucki

      Affiliations

    • University of Lucerne and Swiss Paraplegic Research, Lucerne, Switzerland
    • ,
  • Jeffrey Tobias

      Affiliations

    • NeurogesX, Inc., San Carlos, CA, USA
    • ,
  • Richard E. White

      Affiliations

    • Endo Pharmaceuticals Inc., Chadds Ford, PA, USA
    • ,
  • James Witter

      Affiliations

    • National Institutes of Health, Bethesda, MD, USA

Received 20 October 2009 ,Revised 5 February 2010 ,Accepted 10 February 2010.

References 

  1. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34:505–514
  2. Altman A, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society: results from a workshop. Osteoarthritis Cartilage. 1996;4:217–243
  3. Arends LR, Hoes AW, Lubsen J, Grobbee DE, Stijnen T. Baseline risk as predictor of treatment benefit: three clinical meta-re-analyses. Stat Med. 2000;19:3497–3518
  4. Arnold LM, Crofford LJ, Martin SA, Young JP, Sharma U. The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med. 2007;8:633–638
  5. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974–2984
  6. Babul N, Noveck R, Chipman H, Roth SH, Gana T, Albert K. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage. 2004;28:59–71
  7. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831–1836
  8. Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P, Rauck R, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7:1106–1112
  9. Baron R. Mechanisms of disease: neuropathic pain—a clinical perspective. Nature Clin Pract Neurology. 2006;2:95–106
  10. Baron R, Tölle TR, Gockel U, Brosz M, Freynhagen R. A cross sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences in demographic data and sensory systems. Pain. 2009;146:34–40
  11. Bellamy N, Campbell J, Syrotuik J. Comparative study of self-rating pain scales in rheumatoid arthritis patients. Curr Med Res Opin. 1999;15:113–119
  12. Bellamy N, Campbell J, Syrotuik J. Comparative study of self-rating pain scales in osteoarthritis patients. Curr Med Res Opin. 1999;15:121–127
  13. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5:27–36
  14. Beydoun A, Shaibani A, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Acta Neurol Scand. 2006;113:395–404
  15. Bradley JD, Katz BP, Brandt KD. Severity of knee pain does not predict a better response to an antiinflammatory dose of ibuprofen than to analgesic therapy in patients with osteoarthritis. J Rheumatol. 2001;28:1073–1076
  16. Breuer B, Pappagallo M, Knotkova H, Guleyupoglu N, Wallenstein S, Portenoy RK. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther. 2007;29:2022–2030
  17. Byas-Smith MG, Max MB, Muir J, Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage ‘enriched enrollment’ design. Pain. 1995;60:267–274
  18. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): Progress of an NIH Roadmap Cooperative Group during its first two years. Med Care. 2007;45:S3–11
  19. Cochrane Collaboration. Tool for assessing risk of bias. http://www.ohg.cochrane.org/forms/Risk%20of%20bias%20assessment%20tool.pdf. Accessed September 13, 2009.
  20. Crofford LJ, Mease PJ, Simpson SL, Young JP, Martin SA, Haig GM, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136:419–431
  21. Cruccu G, Anand P, Attal N, Garcia-Larrea L, Haanpaa M, Jorum E, et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol. 2004;11:153–162
  22. Demitrack MA, Faries D, Herrera JM, DeBrota DJ, Potter WZ. The problem of measurement error in multisite clinical trials. Psychopharmacol Bull. 1998;34:19–24
  23. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63:308–315
  24. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002;36:383–390
  25. Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain. 2005;9:543–554
  26. Dworkin RH, Gnann JW, Oaklander AL, Raja SN, Schmader KE, Whitley RJ. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain. 2008;9:S37–44
  27. Dworkin RH, Katz J, Gitlin MJ. Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain. Neurology. 2005;65:S7–19
  28. Dworkin RH, Thakur R, Griesing T, Sharma U, Young JP. Randomized clinical trials of pregabalin for neuropathic pain: methods, results, and implications. Progr Neurother Neuropsychopharmacol. 2008;3:167–187
  29. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9–19
  30. Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain. 2009;146;238–244
  31. Dworkin RH, Turk DC, Peirce-Sandner S, McDermott MP, Farrar JT, Hertz S, Katz NP, Raja SN, Rappaport BA. Placebo and treatment group responses in postherpetic neuralgia vs. painful diabetic peripheral neuropathy clinical trials in the REPORT database. Pain, in press.
  32. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105–121
  33. Dyck PJ, Norell JE, Tritschler H, Schuette K, Samigullin R, Ziegler D, et al. Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity. Diabetes Care. 2007;30:2619–2625
  34. Edwards RR. Individual differences in endogenous pain modulation as a risk factor for chronic pain. Neurology. 2005;65:437–443
  35. Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments, part 2: practical issues and specific cases. Ann Intern Med. 2000;133:464–470
  36. England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, Asbury AK, Szigeti K, Lupski JR, Latov N, Lewis RA, Low PA, Fisher MA, Herrmann DN, Howard JF,Jr, Lauria G, Miller RG, Polydefkis M, Sumner AJ. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009;72:177-184.
  37. European Medicines Agency. Note for guidance on clinical investigation of medicinal products for treatment of nociceptive pain. 2003; available at: www.emea.europa.eu.
  38. European Medicines Agency. Guideline on clinical and medicinal products intended for the treatment of neuropathic pain. 2007; available at: www.emea.europa.eu.
  39. Evers S, Marziniak M, Frese A, Gralow I. Placebo efficacy in childhood and adolescence migraine: an analysis of double-blind and placebo-controlled studies. Cephalalgia. 2008;29:436–444
  40. Faries DE, Heiligenstein JH, Tollefson GD, Potter WZ. The double-blind variable placebo lead-in period: results from two antidepressant clinical trials. J Clin Psychopharmacol. 2001;21:561–568
  41. Fillingim RB. Individual differences in pain responses. Curr Rheumatol Rep. 2005;7:342–347
  42. Finnerup NB, Otto M, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118:289–305
  43. Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain. 2002;96:375–383
  44. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115:254–263
  45. Gallo P, Krams M. PhRMA Working Group on Adaptive Designs: introduction to the full white paper. Drug Inf J. 2006;40:421–423
  46. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324–1334
  47. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet. 2009;374:1252–1261
  48. Gilron I, Wajsbrot D, Therrien F, Lemay J. A randomized, placebo-controlled trial of pregabalin for the treatment of peripheral neuropathic pain. Presented at the meeting of the Canadian Pain Society, Quebec, Canada, May 2009.
  49. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004;24:389–399
  50. Greene WI, Concato J, Feinstein AR. Claims of equivalence in medical research: are they supported by the evidence?. Ann Intern Med. 2000;132:715–722
  51. Grosskopf J, Mazzola J, Wan Y, Hopwood M. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand. 2006;114:177–180
  52. Hale ME, Ahdieh H, Ma T, Rauck R. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007;8:175–184
  53. Hansson PT, Attal N, Baron R, Cruccu G. Toward a definition of pharmacoresistant neuropathic pain. Eur J Pain. 2009;13:439–440
  54. Hansson P, Backonja M, Bouhassira D. Usefulness and limitations of quantitative sensory testing: clinical and research application in neuropathic pain states. Pain. 2007;129:256–259
  55. Henanff AL, Giraudeau B, Baron G, Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. JAMA. 2006;295:1147–1151
  56. Hunt DG, Zuberbier OA, Kozolowski AJ, Robinson J, Berkowitz J, Schultz IZ, et al. Reliability of the lumbar flexion, lumbar extension and passive straight leg raise test in normal populations embedded within a complete physical examination. Spine. 2001;26:2714–2718
  57. International Conference on Harmonization. Dose-response information to support drug registration: E4. 1994; available at: www.fda.gov/cder/guidance/index.htm#ICH_efficacy.
  58. International Conference on Harmonization. Structure and content of clinical study reports: E3. 1996; available at: www.fda.gov/cder/guidance/index.htm#ICH_efficacy.
  59. International Conference on Harmonization. Statistical principles for clinical trials: E9. 1998; available at: www.fda.gov/cder/guidance/index.htm#ICH_efficacy.
  60. International Conference on Harmonization. Choice of control group and related issues in clinical trials: E10. 2001; available at: www.fda.gov/cder/guidance/index.htm#ICH_efficacy.
  61. Irizarry MC, Webb DJ, Ali Z, Chizh BA, Gold M, Kinrade FJ, et al. Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials. Clin J Pain. 2009;25:469–476
  62. Jadad AR, Enkin MW. second ed.. Randomised controlled trials: questions, answers and musings. London: Blackwell; 2007;
  63. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12
  64. Jensen MP, McFarland CA. Increasing the reliability and validity of pain intensity measurement in chronic pain patients. Pain. 1993;55:195–203
  65. Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain. 2003;102:1–8
  66. Jones B, Kenward MG. Design and analysis of cross-over trials. second ed.. Boca Raton, FL: Chapman & Hall; 2003;
  67. Kalso E, Simpson KH, Slappendel R, Dejonckheere J, Richarz U. Predicting long-term response to strong opioids in patients with low back pain: findings from a randomized, controlled trial of transdermal fentanyl and morphine. BMC Med. 2007;5:39
  68. Katz J, Finnerup NB, Dworkin RH. Clinical trial outcome in neuropathic pain: relationship to study characteristics. Neurology. 2008;70:263–272
  69. Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology. 2005;65:S32–49
  70. Katz N. Enriched enrollment randomized withdrawal trial designs of analgesics: focus on methodology. Clin J Pain. 2009;9:797–807
  71. Katz N, Ju WD, Krupa DA, Sperling RS, Bozalis Rodgers D, Gertz BJ, et al. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials. Spine. 2003;28:851–858
  72. Katz N, Rauck R, Ahdieh H, Ma T, Gerritsen van der Hoop R, Kerwin R, et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin. 2007;23:117–128
  73. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med. 2006;145:62–69
  74. Khan A, Khan SR, Walens G, Kolts R, Giller EL. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology. 2003;28:552–557
  75. Khan A, Kolts RL, Thase ME, Krishnan KR, Brown W. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry. 2004;161:2045–2049
  76. Khan A, Redding N, Brown WA. The persistence of the placebo response in antidepressant clinical trials. J Psychiatr Res. 2008;42:791–796
  77. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLOS Med. 2008;5:e45
  78. Kroenke K, Bair MJ, Damush TM, Wu J, Hoke S, Sutherland J, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. JAMA. 2009;301:2099–2110
  79. Kobak KA, Kane JM, Thase ME, Nierenberg AA. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms?. J Clin Psychopharm. 2007;27:1–5
  80. Lambert MF, Woods J. Incorporating patient preferences into randomized trials. J Clin Epidemiol. 2000;53:163–166
  81. Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. Clin Ther. 2007;29:2179–2193
  82. Landin R, DeBrota DJ, DeVries TA, Potter WZ, Demitrack MA. The impact of restrictive entry criterion during the placebo lead-in period. Biometrics. 2000;56:271–278
  83. Lang JM. The use of a run-in to enhance compliance. Stat Med. 1990;9:87–95
  84. Lauritsen K, Innocenti AD, Hendel L, Praest J, Lytje MF, Clemmensen-Rotne K, et al. Symptom recording in a randomizes clinical trial: paper diaries vs. electronic or telephone data capture. Control Clin Trials. 2004;25:585–597
  85. Leber PD. Hazards of inference: the active control investigation. Epilepsia. 1989;30:S57–63
  86. Leber PD. The future of controlled clinical trials: is there an alternative to the randomized controlled trial?. Psychopharmacol Bull. 1991;27:3–8
  87. Leber PD, Davis CS. Threats to the validity of clinical trials employing enrichment strategies for sample selection. Control Clin Trials. 1998;19:178–187
  88. Lee S, Walker JR, Jakul L, Sexton K. Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress Anxiety. 2004;19:10–19
  89. Lemmens HJM, Wada DR, Munera C, Eltahtawy A, Stanski DR. Enriched analgesic efficacy studies: an assessment by clinical trial simulation. Contemp Clin Trials. 2006;27:165–173
  90. Maheu E, Altman RD, Bloch DA, Doherty M, Hochberg M, Mannoni A, et al. Design and conduct of clinical trials in patients with osteoarthritis of the hand: recommendations from a task force of the Osteoarthritis Research Society International. Osteoarthritis Cartilage. 2006;14:303–322
  91. Mallinckrodt CH, Meyers AL, Prakash A, Faries DE, Detke MJ. Simple options for improving signal detection in antidepressant clinical trials. Psychopharm Bull. 2007;40:101–114
  92. Max MB. Towards physiologically based treatment of patients with neuropathic pain. Pain. 1990;42:131–133
  93. Max MB. Neuropathic pain syndromes. In:  Max MB,  Portenoy RK,  Laska EM editor. The design of analgesic clinical trials. Philadelphia, PA: Lippincott-Raven; 1991;p. 193–231
  94. In:  Max MB,  Portenoy RK,  Laska EM editor. The design of analgesic clinical trials. Philadelphia, PA: Lippincott-Raven; 1991;
  95. McGrath PJ, Walco G, Turk DC, Dworkin RH, Brown MT, Davidson K, et al. Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. J Pain. 2008;9:771–783
  96. McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain. Pain. 2008;135:217–220
  97. In:  Merskey H,  Bogduk N editor. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. second ed. Seattle: IASP Press; 1994;
  98. Moyé LA. Multiple analyses in clinical trials. New York: Springer; 2003;
  99. Myers MG, Cairns JA, Singer J. The consent form as a possible cause of side effects. Clin Pharmacol Ther. 1987;42:250–253
  100. Otto M, Bach FW, Jensen TS, Sindrup SH. Health-related quality of life and its predictive role for analgesic effect in patients with painful polyneuropathy. Eur J Pain. 2007;11:572–578
  101. Pablos-Méndez A, Barr RG, Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA. 1998;279:222–225
  102. Perrot S. Should we switch from analgesics to the concept of “Pain Modifying Analgesic Drugs (PMADs)” in osteoarthritis and rheumatic chronic pain conditions?. Pain. 2009;146:229–230
  103. Pfizer, Inc. PhRMA web synopsis (Protocol A0081007): a randomized placebo-controlled trial of the efficacy and safety of pregabalin in the treatment of subjects with neuropathic pain associated with lumbo-sacral radiculopathy. 2008; available at: http://pdf.clinicalstudyresults.org/documents/company-study_4268_0.pdf.
  104. Pfizer, Inc. A randomized, placebo-controlled trial of the efficacy and safety of pregabalin in the treatment of subjects with peripheral neuropathic pain. 2008; available at: http://www.clinicalstudyresults.org/drugdetails/?study_name=A0081084&sort=c.company_name&page=1&drug_id=8627.
  105. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295:1152–11560
  106. Quessy SN. Two-stage enriched enrolment pain trials: a brief review of designs and opportunities for broader application. Pain. 2010;148:8–13
  107. Quessy SN, Rowbotham MC. Placebo response in neuropathic pain trials. Pain. 2008;138:479–483
  108. Raskin P, Donofrio PD, Rosenthal NR, Hewitt DJ, Jordan DM, Xiang J, et al. CAPSS-141 Study Group. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology. 2004;63:865–873
  109. Reimherr FW, Ward MF, Byerley WF. The introductory placebo washout: a retrospective evaluation. Psychiatry Res. 1989;30:191–199
  110. Revicki DA, Chen WH, Harnam N, Cook KF, Antmann D, Callahan LF, et al. Development and psychometric analysis of the PROMIS pain behavior item bank. Pain. 2009;146:158–169
  111. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812–819
  112. Rolke R, Baron R, Maier C, Tölle TR, Treede RD, Beyer A, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain. 2006;123:231–243
  113. Rolke R, Magerl W, Campbell KA, Schalber C, Caspari S, Birklein F, et al. Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur J Pain. 2006;10:77–88
  114. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628–638
  115. Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials. 2006;1:e9
  116. Rothwell PM, Watson CPN. External validity of randomized controlled trials: general principles and lessons from trials in neuropathic pain. In: Casto-Lopes J, editor. Current topics in pain: 12th World Congress on Pain. Seattle, WA: IASP Press; 2009. pp. 199-220.
  117. Rowbotham MC. The impact of selective publication on clinical research in pain. Pain. 2008;140:401–404
  118. Rowbotham MC, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837–1842
  119. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348:1223–1232
  120. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136:432–444
  121. Sackett DL. The competing objectives of randomized trials. N Engl J Med. 1980;303:1059–1060
  122. Sackett DL, Haynes RB. The architecture of diagnostic research. BMJ. 2002;324:539–541
  123. Schatzberg AF, Kraemer HC. Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression. Biol Psychiatry. 2000;47:736–744
  124. Schnitzer TJ, Gray WL, Paster RZ, Kamin M. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol. 2000;27:772–778
  125. Schnitzer TJ, Weaver AL, Polis AB, Petruschke RA, Geba GP. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee: a combined analysis of the VACT studies. J Rheumatol. 2005;32:1093–1105
  126. Scholz J, Mannion RJ, Hord DE, Griffin RS, Rawal B, Zheng H, et al. A novel tool for the assessment of pain: validation in low back pain. PLoS Med. 2009;6:e1000047
  127. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967;20:637–648
  128. Senn S. Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials. Stat Med. 1994;13:293–296
  129. Senn S. Cross-over trials in clinical research. second ed.. West Sussex, England: John Wiley & Sons; 2002;
  130. Senn S. Statistical issues in drug development. second ed.. West Sussex, England: John Wiley & Sons; 2007;
  131. Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008;28:484–495
  132. Silver M, Blum D, Grainger J, Hammer AE, Quessy S. Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manage. 2007;34:446–454
  133. Simpson DM, Clifford D, Schiffito G. Pregabalin in the treatment of painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. American Academy of Neurology, Seattle, WA; April 29, 2009.
  134. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain. 1999;83:85–90
  135. Stacey BR, Barrett JA, Whalen E, Phillips KF, Rowbotham MC. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and tie to onset of pain relief. J Pain. 2008;9:1006–1017
  136. Stacey BR, Dworkin RH, Murphy K, Sharma U, Emir B, Griesing T. Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med. 2008;9:1202–1208
  137. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrolment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain: a systematic review. Br J Clin Pharmacol. 2008;66:266–275
  138. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments, part 1: ethical and scientific issues. Ann Intern Med. 2000;133:455–463
  139. Tesfaye S, Tandan R, Bastyr EJ III, Kles KA, Skljarevski V, Price KL. Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials. Diabetes Care. 2007;30:2626–2632
  140. Thienel U, Neto W, Schwabe SK, Vijapurkar U. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand. 2004;110:221–231
  141. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630–1635
  142. Trivedi MH, Rush H. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?. Neuropsychopharmacology. 1994;11:33–43
  143. Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003;106:337–345
  144. Turk DC, Dworkin RH, Burke LB, Gershon R, Rothman M, Scott J, et al. Developing outcome measures for pain clinical trials: IMMPACT recommendations. Pain. 2006;125:208–215
  145. Turk DC, Dworkin RH, McDermott MP, Bellamy N, Burke LB, Chandler JM, et al. Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Pain. 2008;139:485–493
  146. Turner JA, Jensen MP, Warms CA, Sardenas DD. Blinding effectiveness and association of pretreatment expectations with pain improvement in a double-blind randomized controlled trial. Pain. 2002;99:91–99
  147. Vickers AJ. Statistical reanalysis of four recent randomized trials of acupuncture for pain using analysis of covariance. Clin J Pain. 2004;20:319–323
  148. Vinik AI, Tuchman M, Safirstein B, Corder C, Kirby L, Wilks K, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized double-blind, placebo-controlled studies. Pain. 2007;128:169–179
  149. Wasan AJ, Davar G, Jamison R. The association between negative affect and opioid analgesia in patients with discogenic low back pain. Pain. 2005;117:450–461
  150. Whitney CW, Von Korff M. Regression to the mean in treated versus untreated chronic pain. Pain. 1992;50:281–285
  151. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004;140:441–451
  152. Woolf CJ, Bennett GJ, Doherty M, Dubner R, Kidd B, Koltzenburg M, et al. Towards a mechanism-based classification of pain? Pain. 1998;77:227–229
  153. XenoPort, Inc. Phase II results for GSK1838262 (XP13512) reported for neuropathic pain associated with diabetic peripheral neuropathy. 2009; available at: http://phx.corporate-ir.net/phoenix.zhtml?c=187883&p=irol-newsArticle&ID=1280577&highlight=.
  154. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW, Mullens EL. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain. 1997;73:223–230
  155. Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis. Ann Rhemu Dis. 2008;67:1716–1723
  156. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29:2365–2370
  157. Ziegler D, Pritchett YL, Wang F, Desaiah D, Robinson MJ, Hall JA, et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care. 2007;30:664–669
  158. Zimbroff DL. Patient and rater education of expectations in clinical trials (PREECT). J Clin Psychopharmacol. 2001;21:251–252

PII: S0304-3959(10)00093-X

doi: 10.1016/j.pain.2010.02.018

PAIN
Volume 149, Issue 2 , Pages 177-193 , May 2010

Article Tools

* Image Usage & Resolution